An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis

Inclusion Criteria: * A minimum of 120 male and female patients with chronic kidney disease not requiring dialysis will be screened for participation in the study. * Men or woman 18 years of age or older * If currently taking phosphate binder(s), willing to stop this and enter a 2 week washout period * Willing to avoid any intentional changes in diet such as fasting or dieting * Have the following central laboratory measurements: 1. If not on a phosphate binder, a serum phosphorus measurement ≥ 5.5 mg/dL (1.76 mmol/L) at Screening (Visit1). 2. If taking a phosphate binder(s) at screening, a serum phosphorus measurement ≥ 5.5 mg/dL (1.76 mmol/L) after the two-week washout period at Visit 1a (Day 0). * At Screening (Visit 1), have the following central laboratory measurements: 1. 25-hydroxyvitamin D ≥ 10 ng/mL 2. iPTH ≤ 800 pg/mL * Willing and able to take sevelamer carbonate alone as a phosphate binder for the duration of the study * Willing and able to maintain screening doses of lipid medication, 1,25 dihydroxyvitamin D, and/or cinacalcet for the duration of the study, except for safety reasons * Willing and able to avoid antacids and phosphate binders containing aluminum, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement * If female and of childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or IUDs * Expecting not to initiate dialysis for the duration of this study * Considered compliant with phosphate binders (if applicable) * Willing and able to provide informed consent * Has not participated in any other investigational drug studies within 30 days prior to enrollment, * Level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel Exclusion Criteria: * Active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal (GI) motility disorders * Active ethanol or drug abuse, excluding tobacco use * Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders. * In the opinion of the investigator, patient has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition * Pregnant or breast-feeding * Evidence of active malignancy except for basal cell carcinoma of the skin * Unable to comply with the requirements of the study * Known hypersensitivity to sevelamer or any constituents of the study drug * Any other condition, which in the opinion of the investigator will prohibit the patient's inclusion in the study